| 000 | 01887 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250518074754.0 | ||
| 264 | 0 | _c20201105 | |
| 008 | 202011s 0 0 eng d | ||
| 022 | _a2376-1032 | ||
| 024 | 7 |
_a10.18553/jmcp.2019.19035 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCannon, Anthony J | |
| 245 | 0 | 0 |
_aEvaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets. _h[electronic resource] |
| 260 |
_bJournal of managed care & specialty pharmacy _cFeb 2020 |
||
| 300 |
_a143-153 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBlood Glucose _xdrug effects |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xdrug therapy |
| 650 | 0 | 4 | _aDrug Combinations |
| 650 | 0 | 4 |
_aGlycated Hemoglobin _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemia _xchemically induced |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aInsulin Glargine _xadministration & dosage |
| 650 | 0 | 4 |
_aInsulin, Long-Acting _xadministration & dosage |
| 650 | 0 | 4 |
_aLiraglutide _xadministration & dosage |
| 650 | 0 | 4 |
_aMetformin _xadministration & dosage |
| 650 | 0 | 4 | _aUnited States |
| 700 | 1 | _aBargiota, Alexandra | |
| 700 | 1 | _aBillings, Liana | |
| 700 | 1 | _aHunt, Barnaby | |
| 700 | 1 | _aLeiter, Lawrence A | |
| 700 | 1 | _aMalkin, Samuel | |
| 700 | 1 | _aMocarski, Michelle | |
| 700 | 1 | _aRanthe, Mattis Flyvholm | |
| 700 | 1 | _aSchiffman, Alisa | |
| 700 | 1 | _aDoshi, Ankur | |
| 773 | 0 |
_tJournal of managed care & specialty pharmacy _gvol. 26 _gno. 2 _gp. 143-153 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.18553/jmcp.2019.19035 _zAvailable from publisher's website |
| 999 |
_c30439643 _d30439643 |
||